Related Experiment Video
Updated: Mar 19, 2026
An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
Published on: May 8, 2017
Pharmacoeconomic Impact of Purchasing Off-Label Drugs in Tunisia: Case Study of Pembrolizumab (Keytruda®)
Iheb Tbib1, Sarah Zerei1, Sameh Jellali2
1National Agency for Medicines and Health Products, 40, Hedi Nouira street, 1023, Tunis, Tunisia; Faculty of Pharmacy of Monastir, University of Monastir, 5000, Monastir, Tunisia.
Purpose:
Access to medicines is a universal right guaranteed by Tunisian law and is ensured through 2 pathways: Marketing Authorization (MA) for products approved for national commercialization, or the off-label drug purchase procedure, which allows the importation of medicines not authorized on the Tunisian market. The aim of this study was to assess the current situation of these purchases and their pharmaco-economic impact through a case study of pembrolizumab (Keytruda).
Methods:
This retrospective descriptive study analyzed all off-label drug purchases recorded between 2021 and 2023 using data obtained from the National Agency for Medicines and Health Products' (NAMHP) internal software called "SIAMED". The budget impact analysis of Keytruda (pembrolizumab) was conducted in accordance with the methodological steps recommended by the National Authority for Health Evaluation and Accreditation's guideline and using data of only 2023 from the Central Pharmacy of Tunisia (PCT).
Findings:
The number of purchases rose steadily over the study period by 25.8%, with a predominance of anticancer drugs, particularly immunotherapies with a percentage of 43.76%, at the expense of conventional chemotherapies whose percentage fell to 23.48%. The distribution of therapeutic areas in the public and private sectors showed an interest in anticancer drugs for the public sector, and in drugs for the genito-urinary system for the private sector. The budgetary analysis of Keytruda revealed a marked increase in prescriptions from 42 in 2021 to 266 prescriptions in 2023, generating costs more than 20 million Tunisian dinars (MTND), and showed that granting MA could generate savings of 17,2 MTND.
Implications:
Although this purchasing procedure facilitates access to medicines, its regulatory framework needs to be reviewed. Budget impact analysis is a key tool for optimizing resource management and encouraging the issuance of MA, thereby helping to limit the costs generated by this procedure.
More Related Videos
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
01:29Therapeutic Drug Monitoring: Affecting Factors
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
01:29Pharmacogenomics: Identification of New Drug Targets
01:19Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:02Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...